EP 1448205 A2 20040825 - COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
Title (en)
COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
Title (de)
KOMBINATIONEN FÜR DIE BEHANDLUNG VON IMMUN-ENTZÜNDLICHEN ERKRANKUNGEN
Title (fr)
COMBINAISONS PERMETTANT LE TRAITEMENT DES TROUBLES IMMUNOINFLAMMATOIRES
Publication
Application
Priority
- US 0231866 W 20021004
- US 32767401 P 20011005
Abstract (en)
[origin: WO03030823A2] The invention features a method for treating a patient having an immunoinflammatory disorder, by administering to the patient (i) a tetra-substituted pyrimidopyrimidine, and (ii) a corticosteroid simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit immunoinflammation.
IPC 1-7
IPC 8 full level
A61K 31/56 (2006.01); A61K 31/519 (2006.01); A61K 31/57 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01); A61P 1/04 (2006.01); A61P 3/10 (2006.01); A61P 11/06 (2006.01); A61P 17/00 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 37/02 (2006.01); A61P 43/00 (2006.01)
IPC 8 main group level
A61K (2006.01)
CPC (source: EP KR US)
A61K 31/519 (2013.01 - EP KR US); A61K 31/56 (2013.01 - EP US); A61K 31/573 (2013.01 - EP US); A61K 31/675 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 1/00 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 21/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
Designated extension state (EPC)
AL LT LV MK RO SI
DOCDB simple family (publication)
WO 03030823 A2 20030417; WO 03030823 A3 20030703; AR 036741 A1 20040929; AT E502642 T1 20110415; AU 2002334870 B2 20071004; AU 2002334870 B8 20030422; BR 0213100 A 20041130; CA 2461946 A1 20030417; CA 2461946 C 20100112; CN 100400044 C 20080709; CN 1599613 A 20050323; DE 60239558 D1 20110505; DK 1448205 T3 20111212; EP 1448205 A2 20040825; EP 1448205 A4 20070103; EP 1448205 B1 20110323; EP 2279742 A2 20110202; EP 2279742 A3 20110420; ES 2363334 T3 20110801; HK 1076387 A1 20060120; HR P20040388 A2 20041031; IL 161267 A0 20040927; IS 7202 A 20040331; JP 2005508346 A 20050331; KR 100824491 B1 20080422; KR 100917082 B1 20090915; KR 20050033520 A 20050412; KR 20070100400 A 20071010; MX PA04003266 A 20040708; NO 20041386 L 20040511; NZ 532310 A 20070223; PL 370764 A1 20050530; PT 1448205 E 20110705; RU 2004113551 A 20050227; RU 2322984 C2 20080427; SI 1448205 T1 20110729; TW I247605 B 20060121; US 2003119786 A1 20030626; US 2006234991 A1 20061019; US 2011223621 A1 20110915; US 7253155 B2 20070807; US 7915265 B2 20110329; ZA 200402955 B 20050419
DOCDB simple family (application)
US 0231866 W 20021004; AR P020103758 A 20021004; AT 02800923 T 20021004; AU 2002334870 A 20021004; BR 0213100 A 20021004; CA 2461946 A 20021004; CN 02823996 A 20021004; DE 60239558 T 20021004; DK 02800923 T 20021004; EP 02800923 A 20021004; EP 10013063 A 20021004; ES 02800923 T 20021004; HK 05108422 A 20050923; HR P20040388 A 20040504; IL 16126702 A 20021004; IS 7202 A 20040331; JP 2003533857 A 20021004; KR 20047005050 A 20040406; KR 20077019833 A 20070830; MX PA04003266 A 20021004; NO 20041386 A 20040402; NZ 53231002 A 20021004; PL 37076402 A 20021004; PT 02800923 T 20021004; RU 2004113551 A 20021004; SI 200230946 T 20021004; TW 91123107 A 20021007; US 201113048587 A 20110315; US 26499102 A 20021004; US 35455206 A 20060215; ZA 200402955 A 20040419